Details of the Drug Combination

General Information of Drug Combination (ID: DC8JZ5R)

Drug Combination Name
LIAROZOLE Vinflunine
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs LIAROZOLE   DM4OYXE Vinflunine   DMTJAEP
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: OVCAR3
Zero Interaction Potency (ZIP) Score: 4.65
Bliss Independence Score: 4.85
Loewe Additivity Score: 3.77
LHighest Single Agent (HSA) Score: 3.69

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of LIAROZOLE
Disease Entry ICD 11 Status REF
Dermatological disease DA24.Y Phase 2/3 [2]
LIAROZOLE Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [4]
Cytochrome P450 26 (CYP26A1) TTD7Q0R CP26A_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Vinflunine
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [3]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Papillary renal cell carcinoma DCMY449 ACHN Investigative [6]
Adenocarcinoma DCC10GK HCC-2998 Investigative [1]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5210).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
5 Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem. 2008 Sep 1;16(17):8301-13.
6 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966